Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management

Table 3

Subset analysis of elderly population in clinical trials of angiogenesis inhibitors for NSCLC.

Study	Age	.	Treatment	OS (month)	HR for OS (95% CI)	PFS (month)	HR for PFS (95% CI)
AVAiL [32]	≥65	103	CG + BEV (15 mg/kg)	NR	0.88	NR	0.84
	<65	248	CG + BEV (15 mg/kg)	NR	1.09	NR	0.85
ECOG4599, PointBreak [33]	≥75	114	BEV + CP	9.6	1.10 (0.74–1.60)	5.6	0.95 (0.62–1.44)
	<75	787	BEV + CP	13.4	0.76 (0.66–0.87)	6.1	0.69 (0.60–79)
SAiL [34]	>65	623	Chemotherapy + BEV	14.6	NR	8.2	NR
	≤65	1589	Chemotherapy + BEV	14.6	NR	7.6	NR
ARIES [35]	≥65	1013	Chemotherapy + BEV	12.1	1.17 (1.06–1.28)	6.8	1.01 (0.92–1.10)
	<65	954	Chemotherapy + BEV	14.2	1	6.4	1
REVEL [36, 37]	≥70	127	RAM + DTX	NR	1.07 (0.80–1.43)	NR	0.94 (0.73–1.22)
	<70	591	RAM + DTX	NR	0.81 (0.70–0.94)	NR	0.73 (0.64–0.83)

RR = response rate, OS = overall survival, PFS = progression free survival, HR = hazard ratio, NR = not reported, CG = carboplatin/gemcitabine, BEV = bevacizumab, CP = carboplatin/paclitaxel, DTX = docetaxel, and RAM = ramucirumab.